Baheal Pharma Group has been named among the "Top 30 Strategic Investors / CVCs in China" in Zero2IPO Research Center's 2025 China Venture Capital & Private Equity Annual Ranking, reflecting the Group’s sustained commitment and proven track record in healthcare innovation investment and incubation.

As an authoritative research institution in China's equity investment market, Zero2IPO Research has been compiling and publishing the China Venture Capital & Private Equity Annual Ranking for 25 consecutive years. The rankings are built on a rigorous, objective and transparent methodology, and are widely regarded as a key benchmark for the country’s equity investment landscape, serving as an important reference point for industry development trends.

Baheal Pharma Group is a healthcare industry group driven by technological innovation, with core businesses spanning medical innovation incubation, manufacturing, and commercialization. Leveraging deep insights into clinical needs and advanced incubation mechanisms, Baheal has established a Research and Development Platform through collaborating with leading national research institutions to discover original innovations based on basic biological R&D and innovative achievements investment incubation with First-in-Class potential.

To better support innovative incubation, Baheal leverages the Baheal Zhongxin Fund as a dedicated industrial investment platform. Through this platform, the Group provides end-to-end support for innovative enterprises at different stages of development, including R&D empowerment, clinical advancement, and corporate governance capabilities. These integrated resources help safeguard and accelerate the transition from early-stage research to clinical and commercial application. Today, the Baheal Zhongxin Fund operates a cross-regional network of industry-focused innovation funds and serves as the operational management platform for biopharmaceutical innovation funds in Beijing, Langfang, Suzhou, Qingdao, and other key life sciences hubs. The total assets under management have reached several billion RMB.

In terms of portfolio development, Baheal has advanced a series of innovation programs toward meaningful clinical breakthroughs and substantial progress. These include fully magnetically levitated artificial hearts, medical linear accelerators, innovative radiopharmaceuticals, anti-organ fibrosis therapies, bone regeneration therapeutics, and ASO drugs. These projects address major disease areas of significant public health importance, including cardiovascular diseases, organ fibrosis, and oncology. Several portfolio companies, including BrioHealth and JILUNTAI, have emerged as leaders in their respective fields, further demonstrating Baheal’s professional capabilities in project sourcing and incubation strengths.

Looking ahead, Baheal Pharma Group will continue to uphold its mission of “Better Science, Better Health.” With a forward-looking strategic vision, the Group will further deepen its focus on value investment approach, accelerate the transformation of high-quality scientific and technological achievements into real-world applications, and advance into a new stage as a technology-driven innovative enterprise, injecting sustained vitality into the high-quality development of China’s healthcare industry.